Real Clinical Effectiveness of Molnupiravir Against 30-day
Mortality Among 74 541 SARS-CoV-2-Positive Patients: A
Nationwide Cohort Study From the Czech Republic

CSLog in Log in (EduId)

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 ...

Přehled o publikaci

J 2024

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY et. al.

Basic information

Original name

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

Authors

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY; Vladimir CERNY; Petr ŠTOURAČ; Vlastimil VÁLEK and Ladislav DUŠEK

Edition

OPEN FORUM INFECTIOUS DISEASES, CARY, OXFORD UNIV PRESS INC, 2024, 2328-8957

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.1093/ofid/ofae685

UT WoS

001374759800001

EID Scopus

2-s2.0-85212131397

Keywords in English

30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection

Links

LX22NPO5101, research and development project.

Changed: 7/2/2025 00:50, RNDr. Daniel Jakubík

Abstract

V originále

lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.

Files attached

https://is.muni.cz/publication/2475062/Real_Clinical_Effectiveness_of_Molnupiravir_Against_30-day_Mortality_Among_74_541_SARS-CoV-2-Positive_Patients_A_Nationwide_Cohort_Study_From_the_Czech_Republic.pdf

Cite

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY; Vladimir CERNY; Petr ŠTOURAČ; Vlastimil VÁLEK and Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. OPEN FORUM INFECTIOUS DISEASES. CARY: OXFORD UNIV PRESS INC, 2024, vol. 11, No 12, p. 1-10. ISSN 2328-8957. Available from: https://dx.doi.org/10.1093/ofid/ofae685.

@article{67808,
   author = {Pavlík, Tomáš and Jarkovský, Jiří and Šanca, Ondřej and Koziar Vasakova, Martina and Dlouhy, Pavel and Cerny, Vladimir and Štourač, Petr and Válek, Vlastimil and Dušek, Ladislav},
   article_location = {CARY},
   article_number = {12},
   doi = {http://dx.doi.org/10.1093/ofid/ofae685},
   keywords = {30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection},
   language = {eng},
   issn = {2328-8957},
   journal = {OPEN FORUM INFECTIOUS DISEASES},
   title = {Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic},
   url = {https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true},
   volume = {11},
   year = {2024}
}

TY  - JOUR
ID  - 67808
AU  - Pavlík, Tomáš - Jarkovský, Jiří - Šanca, Ondřej - Koziar Vasakova, Martina - Dlouhy, Pavel - Cerny, Vladimir - Štourač, Petr - Válek, Vlastimil - Dušek, Ladislav
PY  - 2024
TI  - Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic
JF  - OPEN FORUM INFECTIOUS DISEASES
VL  - 11
IS  - 12
SP  - 1-10
EP  - 1-10
PB  - OXFORD UNIV PRESS INC
SN  - 2328-8957
KW  - 30-day all-cause mortality
KW  - COVID-19
KW  - COVID-19-related mortality
KW  - molnupiravir
KW  - SARS-CoV-2 infection
UR  - https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true
N2  - lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
ER  -

PAVLÍK, Tomáš; Jiří JARKOVSKÝ; Ondřej ŠANCA; Martina KOZIAR VASAKOVA; Pavel DLOUHY; Vladimir CERNY; Petr ŠTOURAČ; Vlastimil VÁLEK and Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. \textit{OPEN FORUM INFECTIOUS DISEASES}. CARY: OXFORD UNIV PRESS INC, 2024, vol.~11, No~12, p.~1-10. ISSN~2328-8957. Available from: https://dx.doi.org/10.1093/ofid/ofae685.